Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B OverviewTrack Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B's EBIT ($2.1B) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
As of the most recent data (June 2026), BDXB shows a EBIT of $2.1B. That compares with $2.5B in the prior-year period — down 15.8% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BDXB's EBIT is now $2.1B (was $2.5B) — a 15.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B is outperforming or lagging.
The Healthcare sector average EBIT is about $110B. Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B is at $2.1B, which is lower that average. That is roughly 98.0% below the sector mean. Use the comparison chart on this page to see how BDXB stacks up against individual peers as well.
Tracking BDXB's ebit over time shows whether Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B is scaling, shrinking, or reshaping that part of the business. The current reading is $2.1B That compares with $2.5B in the prior-year period — down 15.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $2.1B) with ownership activity and broader fundamentals.
